Understanding respiratory syncytial virus infection to improve treatment and immunity

P. A. González, L. J. Carreño, S. M. Bueno, C. A. Riedel, A. M. Kalergis

Resultado de la investigación: Review article

12 Citas (Scopus)

Resumen

Despite significant research since it was discovered more than 50 years ago, respiratory syncytial virus (RSV) continues to be the leading agent causing infant hospitalization and respiratory distress worldwide. Although RSV normally does not cause mortality, this virus is recognized as a major public health and economic burden around the globe. RSV can modulate host immunity leading to an inflammatory response that produces lung damage and virus dissemination in the host airways. Remarkably, infection with the virus elicits poor immunity that in most cases fails to protect against subsequent exposures. Here, we review advances made on the understanding of the lifecycle of the virus, some of the molecular mechanisms it has evolved to cause pathology and ineffective immunity during infection. Hopefully, ongoing research will contribute to developing new drugs and candidate vaccines that will decrease the health burden caused by this virus.

Idioma originalEnglish
Páginas (desde-hasta)1122-1139
Número de páginas18
PublicaciónCurrent Molecular Medicine
Volumen13
N.º7
DOI
EstadoPublished - 15 ago 2013

Huella dactilar

Respiratory Syncytial Virus Infections
Viruses
Respiratory Syncytial Viruses
Immunity
Virus Diseases
Therapeutics
Research
Hospitalization
Vaccines
Public Health
Economics
Pathology
Lung
Mortality
Health
Public health
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology

Citar esto

González, P. A. ; Carreño, L. J. ; Bueno, S. M. ; Riedel, C. A. ; Kalergis, A. M. / Understanding respiratory syncytial virus infection to improve treatment and immunity. En: Current Molecular Medicine. 2013 ; Vol. 13, N.º 7. pp. 1122-1139.
@article{2f0a252545cc438c97a53800ab89b704,
title = "Understanding respiratory syncytial virus infection to improve treatment and immunity",
abstract = "Despite significant research since it was discovered more than 50 years ago, respiratory syncytial virus (RSV) continues to be the leading agent causing infant hospitalization and respiratory distress worldwide. Although RSV normally does not cause mortality, this virus is recognized as a major public health and economic burden around the globe. RSV can modulate host immunity leading to an inflammatory response that produces lung damage and virus dissemination in the host airways. Remarkably, infection with the virus elicits poor immunity that in most cases fails to protect against subsequent exposures. Here, we review advances made on the understanding of the lifecycle of the virus, some of the molecular mechanisms it has evolved to cause pathology and ineffective immunity during infection. Hopefully, ongoing research will contribute to developing new drugs and candidate vaccines that will decrease the health burden caused by this virus.",
keywords = "Dendritic cells, Immune evasion, Immune modulation, Prophylaxis, T cells, Vaccine, Virus infective cycle",
author = "Gonz{\'a}lez, {P. A.} and Carre{\~n}o, {L. J.} and Bueno, {S. M.} and Riedel, {C. A.} and Kalergis, {A. M.}",
year = "2013",
month = "8",
day = "15",
doi = "10.2174/1566524011313070007",
language = "English",
volume = "13",
pages = "1122--1139",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

Understanding respiratory syncytial virus infection to improve treatment and immunity. / González, P. A.; Carreño, L. J.; Bueno, S. M.; Riedel, C. A.; Kalergis, A. M.

En: Current Molecular Medicine, Vol. 13, N.º 7, 15.08.2013, p. 1122-1139.

Resultado de la investigación: Review article

TY - JOUR

T1 - Understanding respiratory syncytial virus infection to improve treatment and immunity

AU - González, P. A.

AU - Carreño, L. J.

AU - Bueno, S. M.

AU - Riedel, C. A.

AU - Kalergis, A. M.

PY - 2013/8/15

Y1 - 2013/8/15

N2 - Despite significant research since it was discovered more than 50 years ago, respiratory syncytial virus (RSV) continues to be the leading agent causing infant hospitalization and respiratory distress worldwide. Although RSV normally does not cause mortality, this virus is recognized as a major public health and economic burden around the globe. RSV can modulate host immunity leading to an inflammatory response that produces lung damage and virus dissemination in the host airways. Remarkably, infection with the virus elicits poor immunity that in most cases fails to protect against subsequent exposures. Here, we review advances made on the understanding of the lifecycle of the virus, some of the molecular mechanisms it has evolved to cause pathology and ineffective immunity during infection. Hopefully, ongoing research will contribute to developing new drugs and candidate vaccines that will decrease the health burden caused by this virus.

AB - Despite significant research since it was discovered more than 50 years ago, respiratory syncytial virus (RSV) continues to be the leading agent causing infant hospitalization and respiratory distress worldwide. Although RSV normally does not cause mortality, this virus is recognized as a major public health and economic burden around the globe. RSV can modulate host immunity leading to an inflammatory response that produces lung damage and virus dissemination in the host airways. Remarkably, infection with the virus elicits poor immunity that in most cases fails to protect against subsequent exposures. Here, we review advances made on the understanding of the lifecycle of the virus, some of the molecular mechanisms it has evolved to cause pathology and ineffective immunity during infection. Hopefully, ongoing research will contribute to developing new drugs and candidate vaccines that will decrease the health burden caused by this virus.

KW - Dendritic cells

KW - Immune evasion

KW - Immune modulation

KW - Prophylaxis

KW - T cells

KW - Vaccine

KW - Virus infective cycle

UR - http://www.scopus.com/inward/record.url?scp=84881326943&partnerID=8YFLogxK

U2 - 10.2174/1566524011313070007

DO - 10.2174/1566524011313070007

M3 - Review article

AN - SCOPUS:84881326943

VL - 13

SP - 1122

EP - 1139

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 7

ER -